A Look at AtriCure Inc (ATRC) After 3.0% Gain -- GF Value $39.53 vs Price $48.98
AtriCure Inc (ATRC) shares rose 3.0% to $48.98, significantly above its GF Value™ of $39.53, indicating it is 23.9% overvalued. The company has a GF Score™ of 79/100, with strong financial strength and growth but lower profitability. While some gurus are increasing their stakes, insider selling of $3.0 million without buying raises a red flag for potential investors.
AtriCure stock hits 52-week high at 48.47 USD
AtriCure Inc. (ATRC) reached a new 52-week high of $48.47, reflecting significant stock value growth of 28.54% over the past year and 45.76% in the last six months. Despite this, InvestingPro analysis indicates the stock may be overvalued and its RSI suggests it's in overbought territory. The company recently surpassed Q2 2026 earnings expectations but issued a cautious outlook for the rest of the year.
Advisors Capital Management LLC Takes Position in AtriCure, Inc. $ATRC
Advisors Capital Management LLC has acquired a new position in AtriCure, Inc. (NASDAQ:ATRC), purchasing 174,496 shares valued at approximately $4.88 million. Other institutional investors like Smartleaf Asset Management LLC, Scotia Capital Inc., ProShare Advisors LLC, Captrust Financial Advisors, and Mackenzie Financial Corp also adjusted their holdings in the medical device company. Insider transactions show recent stock sales by Vinayak Doraiswamy and Justin J. Noznesky, while Wall Street analysts maintain a "Moderate Buy" consensus rating with a target price of $48.50 for ATRC.
134,207 Shares in AtriCure, Inc. $ATRC Acquired by Rice Hall James & Associates LLC
Rice Hall James & Associates LLC has acquired 134,207 shares of AtriCure, Inc. (NASDAQ:ATRC) valued at approximately $3.76 million, as disclosed in their latest 13F filing. This acquisition is part of a broader trend of institutional investment in AtriCure, with hedge funds and other institutional investors collectively owning 99.11% of the company's stock. Despite some insider selling, analysts maintain a positive outlook with a "Moderate Buy" consensus rating and an average price target of $48.50.
AllianceBernstein L.P. (ATRC) reports 5.5% beneficial ownership in AtriCure
AllianceBernstein L.P. has filed an amended Schedule 13G, disclosing a 5.5% beneficial ownership in AtriCure Inc., amounting to 2,768,365 shares as of June 30, 2026. These shares are held for investment purposes in client discretionary investment advisory accounts, with AllianceBernstein exercising sole voting power over 2,631,027 shares and sole dispositive power over 2,737,665 shares. The filing clarifies that AllianceBernstein, while a subsidiary of Equitable Holdings, operates under independent management.
Assenagon Asset Management S.A. Buys New Position in AtriCure, Inc. $ATRC
Assenagon Asset Management S.A. has initiated a new position in AtriCure, Inc. (NASDAQ:ATRC), purchasing 62,334 shares valued at approximately $1.74 million. This move comes as AtriCure reported strong quarterly earnings, exceeding revenue estimates with $153.6 million and achieving an EPS of $0.18. Despite positive analyst sentiment leading to a "Moderate Buy" rating and a $48.50 target price, insiders have sold a significant number of shares totaling $1.78 million over the past three months.
AtriCure (ATRC) Is Up 10.1% After Unveiling 2030 Revenue Goal And Trial-Driven Expansion Plans
AtriCure (ATRC) saw a 10.1% stock increase after announcing a goal of US$1.00 billion in revenue by 2030, driven by its atrial fibrillation, left atrial appendage management, and postsurgical pain-management franchises, alongside new product launches. The company's expansion plans heavily rely on the successful outcomes of its BoxX-NoAF and LeAAPS clinical trials, which could broaden the clinical applications for its devices. Despite competitive risks, these trials and new product developments are key catalysts for AtriCure's future growth and could significantly impact its market position.
AtriCure, Inc. - Common Stock (ATRC) Stock Price, News, Quote & History
This page provides a comprehensive overview of AtriCure, Inc. (ATRC) stock, including its current price, key financial metrics, and recent news. AtriCure is a medical device company specializing in treatments for atrial fibrillation and other cardiac conditions, focusing on minimally invasive surgical procedures. The news section highlights recent earnings reports, investor conference participations, and insider stock transactions, reflecting the company's ongoing growth and financial activities.
AtriCure (NASDAQ:ATRC) Sets New 12-Month High - Here's Why
AtriCure (NASDAQ:ATRC) reached a new 52-week high of $43.18, trading above its 50-day and 200-day moving averages. The company reported strong quarterly earnings, exceeding revenue estimates with $153.6 million and $0.18 EPS. Despite significant institutional ownership, insiders have sold shares totaling $1.78 million in the past 90 days.
ATRC: Strong growth, innovation, and clinical trial catalysts drive robust financial and market expansion
AtriCure, Inc. (ATRC) is experiencing strong growth and profitability, maintaining leadership in AFib and pain management. The company's financial performance is bolstered by innovation and operational leverage, with significant clinical trials expected to expand market opportunities. Free cash flow will be directed towards organic growth and research and development efforts.
AtriCure (ATRC) Lifted Its Guidance, Is The Stock Fully Priced?
AtriCure (ATRC) has seen insider share sales despite reporting 13% Q2 revenue growth, returning to net income, and raising full-year guidance. While one valuation narrative suggests the stock is 11.9% undervalued at $47.00 due to potential market expansion from clinical trials, another analysis using a Discounted Cash Flow model indicates a fair value of only $0.73 per share. This divergence in valuation suggests mixed signals regarding ATRC's future stock price.
AtriCure (ATRC) Lifted Its Guidance, Is The Stock Fully Priced?
AtriCure (ATRC) has seen insider share sales despite reporting 13% Q2 revenue growth, a return to net income, and raised full-year guidance. The stock has experienced strong recent share price momentum but is still down significantly over five years. While one narrative suggests the stock is 11.9% undervalued with a fair value of $47.00, another view based on discounted cash flow suggests a significantly lower fair value of $0.73 per share, indicating mixed signals for investors.
Discipline and Rules-Based Execution in ATRC Response
This article analyzes Atricure Inc. (NASDAQ: ATRC), highlighting strong near and mid-term sentiment but a weak long-term outlook. It provides AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal analysis, showing support and resistance levels for different time horizons.
AtriCure (NASDAQ:ATRC) Director Sells $138,283.20 in Stock
AtriCure (NASDAQ:ATRC) Director Karen Prange sold 3,564 shares of the company's stock for $138,283.20. This transaction reduced her holdings by 13.51%. The medical device company recently reported strong quarterly earnings, exceeding analyst estimates, and has received a "Moderate Buy" consensus rating from analysts with a price target of $48.50.
Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors
Two AtriCure directors, including Maggie Yuen, sold shares after a strong second quarter where the company reported 13% revenue growth and raised its full-year outlook. Yuen sold 3,500 shares, reducing her direct equity stake by 20%, though the timing of sales by multiple directors suggests a trading window opening rather than a negative outlook on the company. The article emphasizes that continued execution is more critical for future stock performance than these insider share sales.
AtriCure Inc (ATRC) Stock News Today
This article provides the latest stock news for AtriCure Inc (ATRC), detailing its current stock price, market capitalization, and performance metrics. It also highlights that more news, earnings, analyst ratings, and key developments will be available soon.
AtriCure director Maggie Yuen sells $134,470 in stock
AtriCure director Maggie Yuen sold 3,500 shares of the company's common stock for a total of $134,470 on August 5, 2026, with shares trading between $38.37 and $38.43. Following the sale, Yuen directly holds 14,015 shares. The sale occurred while AtriCure's stock is near its 52-week high, and an InvestingPro analysis suggests the company may be overvalued despite recent strong Q2 2026 earnings that beat Wall Street expectations.
AtriCure (ATRC) director Maggie Yuen reports sale of 3,500 shares
AtriCure director Maggie Yuen sold 3,500 shares of Common Stock on August 5, 2026, at a weighted average price of $38.42 per share, totaling approximately $134,470. The shares were sold in multiple trades ranging from $38.37 to $38.43, and she now directly holds 14,015 shares. The sale was not conducted under a Rule 10b5-1 trading plan.
AtriCure Inc (ATRC) Director Karen Prange Sells 3,564 Shares
AtriCure Inc (ATRC) Director Karen Prange sold 3,564 shares of the company on August 5, 2026, for a total value of approximately $138,283. This sale contributes to a pattern of 14 insider sells and no buys over the past year. The stock is currently deemed "Fairly Valued" by GuruFocus's GF Value model, trading near its estimated intrinsic value.
AtriCure (NASDAQ:ATRC) Director Sells 3,500 Shares
AtriCure Director Maggie Yuen sold 3,500 shares of the company's stock for $134,470, reducing her direct stake by nearly 20%. The medical device company recently reported strong quarterly earnings, exceeding analyst revenue estimates, and provided positive fiscal 2026 EPS guidance. Analysts maintain a "Moderate Buy" rating for AtriCure, with an average price target of $48.50.
AtriCure director Maggie Yuen sells 3,500 shares worth $134,470
AtriCure director Maggie Yuen sold 3,500 common shares on August 5th at a price of $38.42 per share, totaling $134,470. Following this transaction, her direct holdings in the company decreased to 14,015 shares. This information was sourced from an EDGAR filing by AtriCure Inc.
Director At AtriCure Sells $134K Of Stock
AtriCure Director Maggie Yuen sold 3,500 shares of the company's stock for a total of $134,470, as reported in an SEC filing on August 7. The company's shares were trading up 2.89% at $39.49 following the report. AtriCure demonstrated strong revenue growth of 12.83% and maintains a healthy debt-to-equity ratio, though its market capitalization and EPS are below industry averages, while its P/E and P/S ratios are higher.
AtriCure director Maggie Yuen sells $134,470 in stock
AtriCure Director Maggie Yuen sold 3,500 shares of the company's common stock for $134,470 on August 5, 2026. This transaction leaves Yuen with 14,015 shares. The sale occurred while AtriCure's stock is trading near its 52-week high, despite the company recently surpassing Q2 2026 earnings expectations but facing a cautious outlook from investors.
AtriCure, Inc. (ATRC) director sells 3,564 shares at $38.80
AtriCure, Inc. director Karen Prange sold 3,564 shares of common stock at $38.80 per share on August 5, 2026, in an open market or private transaction. Following this sale, Prange directly holds 22,809 shares of AtriCure. The transaction was reported in a Form 4 filing with the SEC.
AtriCure, Inc. (NASDAQ:ATRC) Receives Average Rating of "Moderate Buy" from Analysts
AtriCure, Inc. (NASDAQ:ATRC) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $48.50. The company recently reported strong quarterly results, exceeding EPS and revenue estimates, and provided positive fiscal year 2026 guidance. While institutional ownership is high at 99.11%, insiders have sold shares recently, and the stock trades at a high P/E ratio.
AtriCure, Inc. SEC Filing (Aug 5, 2026)
This article reports on an SEC Form 144 filing by AtriCure, Inc. (ATRC) on August 5, 2026. The filing indicates a proposed sale of 3,500 common shares acquired through restricted stock, with an aggregate market value of $134,467.90, to be sold via Morgan Stanley Smith Barney LLC. The filing was accepted by the SEC on the same day.
AtriCure (ATRC) insider plans NASDAQ sale of 3,564 awarded shares
AtriCure, Inc. insider Karen Prange has filed a notice of intent to sell 3,564 shares of common stock on NASDAQ, which were awarded on May 26, 2023. This Form 144 filing indicates that the shares are held through Fidelity Brokerage Services LLC. Over the past three months, Prange has also sold 3,000 shares of AtriCure common stock in two separate transactions in May 2026.
Will AtriCure’s (ATRC) Profit Turn and ESOP Share Plans Recast Its Investment Narrative?
AtriCure (ATRC) recently reported a shift to net income in Q2 2026, with higher revenue and positive full-year guidance, suggesting improving operating leverage. While ESOP-related share registrations indicate potential dilution, the company's profitability and guidance update strengthen its investment narrative, though competitive pressures from new technologies remain a key consideration. Investors should weigh the improved financial outlook against potential dilution and industry competition.
Form 4 AtriCure Inc For: 3 August By Investing.com
This article reports on a Form 4 filing for AtriCure Inc. (ATRC) on August 3rd. It is a brief, factual announcement from Investing.com, providing no additional details or analysis beyond the filing date and company. The article also includes various market data and related news but does not elaborate on the Form 4 content.
Form 4 AtriCure Inc For: 3 August By Investing.com
This article reports on a Form 4 filing for AtriCure Inc. on August 3rd. It is a brief announcement without further details, indicating a transaction or change in beneficial ownership that the company filed with the SEC.
AtriCure, Inc. (ATRC) CEO makes 4,700-share stock gifts to family, charity
Michael H. Carrel, CEO of AtriCure, Inc. (ATRC), reported bona fide gifts of 4,700 shares of common stock on July 30, 2026. These gifts included 700 shares to a parent and 4,000 shares to a charity, all without consideration. The filing also details his indirect holdings for which he disclaims beneficial ownership except for his pecuniary interest.
Board Member At AtriCure Exercises Options Worth $491K
Sven Wehrwein, a Board Member at AtriCure (NASDAQ: ATRC), exercised stock options worth $491,500 for 25,000 shares on July 30, according to an SEC filing. Despite the insider transaction, AtriCure shares were down by 6.06% on Friday morning. The article also provides a financial overview of AtriCure, highlighting its revenue growth, profitability metrics, debt management, and valuation.
AtriCure (ATRC) Looks Repriced As Strong Q2 Earnings And Higher Guidance Reset The Story
AtriCure (ATRC) has seen a significant stock price rebound following strong Q2 earnings of US$153.6 million in revenue and US$8.96 million in net income, along with updated 2026 guidance. While the stock's short-term performance is positive, its long-term (3-year) return remains down, prompting a re-evaluation of its valuation. Different financial models present conflicting views on whether the company is undervalued or overvalued, suggesting investors should conduct their own thorough analysis of its growth potential and risks.
AtriCure (ATRC) Looks Repriced As Strong Q2 Earnings And Higher Guidance Reset The Story
AtriCure (ATRC) has seen significant repricing following strong Q2 earnings, reporting US$153.6 million in revenue and US$8.96 million in net income, coupled with raised 2026 guidance. While recent stock performance has been robust, opinions diverge on its valuation, with some models suggesting it is undervalued and others indicating overvaluation based on future cash flows. The company's innovative devices and the trend toward minimally invasive cardiac procedures are cited as key drivers for revenue growth.
AtriCure, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ATRC) 2026-07-30
AtriCure, Inc. (ATRC) published its Q2 2026 earnings call presentation on July 30, 2026. The company reported EPS of $0.18, beating estimates by $0.16, and revenue of $153.60 million, a 12.83% year-over-year increase, beating estimates by $1.79 million. This article provides access to the slide deck presented during the earnings call.
AtriCure, Inc. (ATRC) insider sells 6,182 shares at $38.80
AtriCure, Inc.'s Chief Marketing & Strategy Officer, Justin J. Noznesky, sold 6,182 shares of common stock on July 29, 2026, at a weighted average price of $38.80 per share. The transaction, executed in multiple trades, resulted in Noznesky directly holding 100,219 shares of the company's common stock afterwards. This insider sale was reported via an SEC Form 4 filing.
AtriCure (NASDAQ: ATRC) director exercises 25,000 options and sells 25,000 shares
AtriCure director Sven Wehrwein exercised 25,000 non-qualified stock options at $19.95 per share and subsequently sold all 25,000 resulting shares at a weighted average price of $37.84 per share on July 28, 2026. Following these transactions, no options remain outstanding under this specific grant, though Wehrwein still holds 40,518 shares of common stock directly. The SEC Form 4 filing details the exercise and sale, showing total sale proceeds of approximately $946,000 against an exercise cost of $499,000.
Are Options Traders Betting on a Big Move in AtriCure Stock?
Options traders are showing significant interest in AtriCure (ATRC) stock, with the Sep 18, 2026 $50 Call exhibiting high implied volatility, suggesting expectations of a large price movement. Despite this, analysts currently rate AtriCure as a Zacks Rank #3 (Hold), and recent earnings estimates have been revised downward. This divergence indicates a potential opportunity for experienced options traders to sell premium.
AtriCure (ATRC) insider plans Rule 144 sale of 6,182 common shares
AtriCure, Inc. has filed a Rule 144 notice for a proposed sale of 6,182 common shares with an aggregate value of $239,882.00. The shares, acquired through stock grants in 2023 and 2024, are planned to be sold on the NASDAQ market via RBC Capital Markets LLC. This filing indicates an insider's intent to sell a portion of their holdings.
ETFs Investing in AtriCure, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold shares of AtriCure, Inc. (ATRC). It provides a comprehensive table detailing each fund's market value, weight of ATRC stock, issuer, management style, focus, expense ratio, assets under management (AUM), price, change, relative volume, and 3-year NAV total return. The ETFs predominantly target small-cap and healthcare sectors, making investing in ATRC more accessible and diversified.
UC co-op helps build career pathways at AtriCure
The article highlights the strong partnership between the University of Cincinnati's co-op program and AtriCure, a medical device company. Many UC students, especially in biomedical engineering, gain invaluable real-world experience at AtriCure, with numerous alumni continuing to work there full-time. This collaboration provides significant career pathways for students and a vital talent pipeline for the company.
AtriCure Number of Employees 2026 | Employee Count & Headcount Data
AtriCure, Inc. (ATRC) had approximately 1,368 employees worldwide as of March 2026, marking a 21.7% growth from 2023, though experiencing a 0.4% year-over-year decline in 2026. The company is actively hiring, with 216 job postings in 2026, and its workforce is predominantly in North America, with an average salary of $119,704. Employee sentiment is neutral but declining.
UC Co-op Helps Build Career Pathways At AtriCure
The article highlights the successful cooperative education (co-op) program between the University of Cincinnati (UC) and AtriCure, a global medical device company. Many UC students gain real-world experience at AtriCure, often leading to full-time employment after graduation. The program, which started over two decades ago, provides a vital talent pipeline for AtriCure and prepares students for successful careers in engineering and related fields.
AtriCure (ATRC) investor plans to sell 6,000 shares in Rule 144 filing
A shareholder of AtriCure, Inc. (ATRC), Vinayak Doraiswamy, has filed a Form 144 to sell 6,000 common shares through Morgan Stanley Smith Barney LLC Executive Financial Services. The proposed sale is scheduled for July 28, 2026, with an aggregate market value of $233,278.80. These shares stem from performance share awards granted on March 1, 2023, and March 1, 2025.
AtriCure, Inc. SEC Filing (Jul 28, 2026)
This article details an SEC Form 144 filing by AtriCure, Inc. (ATRC) on July 28, 2026, indicating a proposed sale of 25,000 shares of common stock with an aggregate market value of $964,444.00. The shares were acquired through a stock option exercise from the issuer on the same date and are intended to be sold on NASDAQ via Morgan Stanley Smith Barney LLC. The filing shows no previous sales in the past three months from the reporting person.
AtriCure, Inc. 2026: Revenue $153.6M, EPS $0.18— 10-Q Summary
AtriCure, Inc. reported its 2026 quarter results, showing a significant revenue increase to $153.6M, up 12.8% year-over-year. The company returned to net income with diluted EPS of $0.18, compared to a loss in the prior year. Growth was driven by strong U.S. demand and product mix improvements, despite a decline in minimally invasive ablation procedures due to the adoption of pulsed field ablation.
AtriCure, Inc. Quarterly Earnings Report
AtriCure, Inc. (ATRC) filed its Form 10-Q for the quarter ended June 30, 2026, reporting $167,786 thousand in cash and $61,000 thousand in debt. The company achieved $9,063 thousand in net income and $18,196 thousand in operating cash flow for the six months, a significant improvement from a net loss in the prior-year period. Revenue increased by 13.5% worldwide, driven by strong performance in pain management, appendage management, and open ablation product lines.
AtriCure’s Profitability Inflection and 2026 Guidance Could Be A Game Changer For AtriCure (ATRC)
AtriCure, Inc. (ATRC) reported a significant profitability inflection in Q2 2026, moving from a net loss to positive earnings, achieving US$153.6 million in revenue and US$8.96 million in net income. The company issued full-year 2026 guidance forecasting US$602 million to US$610 million in revenue and US$0.05 to US$0.13 net income per share. This shift is crucial for investors, although competitive pressures from pulsed field ablation technologies remain a key risk despite the positive financial outlook.
Inspire's New Director Comes From AtriCure, Which Helped Over 1M Patients
Inspire Medical Systems (NYSE: INSP) has appointed Michael H. Carrel, a seasoned medical device executive and former CEO of AtriCure (NASDAQ: ATRC), to its Board of Directors. Carrel brings extensive experience, having grown AtriCure's revenue significantly and overseeing the treatment of over one million patients. His appointment is expected to provide valuable guidance as Inspire advances its therapy for obstructive sleep apnea, leveraging his expertise in developing and commercializing minimally invasive treatments.
ATRC|AtriCure Inc|Price:35.040|Chg%:+2.040
This article provides a detailed company profile of AtriCure Inc (ATRC), a medical technology company specializing in treatments for atrial fibrillation, LAA management, and post-operative pain. It outlines the company's business scope, financial data including its market cap and revenue sources, and lists key executives along with their shareholdings. The report also highlights institutional ownership and the primary revenue-generating segment for the company.
